Xeris Biopharma Holdings, Inc. (XERS) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-04-21

Key Insights

Dr. Jeffrey Sherman is retiring from the Board effective at the 2026 Annual Meeting after serving since 2021, with the Board reducing from eight to seven directors as a result.
The retirement is characterized as non-contentious, with explicit confirmation that Sherman's departure was not due to disagreements with management or company operations, suggesting stable governance.
Sherman's departure removes representation from both the Compensation Committee and Nominating and Corporate Governance Committee, which may require the Board to reallocate committee responsibilities among remaining directors.

Want the newest filings?

This analysis covers the filing from 2026-04-21. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-01-08

Xeris Biopharma Holdings, Inc. has provided preliminary financial results for Q4 and FY 2025, indicating the company's performance and potential near-term outlook.
The filing does not provide details on specific revenue, earnings, or other key financial metrics, limiting the ability to assess the company's underlying performance.
Investors will likely await the full Q4 and FY 2025 earnings report to gain a more comprehensive understanding of Xeris Biopharma's financial and operational results.

Other reports for Xeris Biopharma Holdings, Inc.

Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.